Tools for Practice Outils pour la pratique


#403 A Whiff of Prevention: Treating Male Partners to Reduce Bacterial Vaginosis Recurrence


CLINICAL QUESTION
QUESTION CLINIQUE
Does treating male sexual partners of females undergoing treatment for bacterial vaginosis infection decrease recurrence?


BOTTOM LINE
RÉSULTAT FINAL
For women undergoing bacterial vaginosis treatment, simultaneously treating male partners with metronidazole alone is ineffective.  However, treating male partners with a combination of topical clindamycin and oral metronidazole may reduce the rate of bacterial vaginosis recurrence to 35% from 63% (no treatment) at 12 weeks based on 1 randomized, controlled trial (RCT).  Considering the limited harms, this combination may be reasonable in male partners.



CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session



EVIDENCE
DONNÉES PROBANTES
  • Results statistically different unless stated.
  • Two newer, higher-quality Most females received oral metronidazole 400-500mg twice daily for 7 days:
  • Open-label RCT (164 couples, 87% previous bacterial vaginosis, monogamous relationship ~14 months). 1 Partners given oral metronidazole 400mg and clindamycin 2% cream twice daily for 7 days, or no treatment.
    • Recurrence at 12 weeks: 35% versus 63% (control), Number Needed To Treat=4
    • Mean time to recurrence: 74 days versus 55 days (control).
    • Adverse events, males:
      • Oral: Nausea (14%), headache (12%), metallic taste (7%).
      • Topical: Penile redness (4%) and irritation (7%).
      • Control arm not reported.
    • Stopped early for benefit (may overestimate benefit).
  • Double-blind RCT (214 females with ≥2 infections in past year, 14-18% had ≥2 partners in previous 3 months).² Partners given oral metronidazole or placebo for 7 days. At 16 weeks:
    • Treatment failure: No difference.
    • Adverse events: No difference.
    • Stopped early for futility.
  • Older systematic review, 7 RCT (1026 participants), partners treated with oral antibiotics alone: no effect.3 Limitations include some non-standard treatments (example: oral metronidazole 2g single dose).
 

CONTEXT
CONTEXTE
  • Clindamycin cream applied to glans penis, upper shaft and under foreskin (if uncircumcised).1
  • Guidelines recommend:4,5
    • In females: Metronidazole 500mg orally twice daily or clindamycin 2% vaginal cream daily for 7 days; or metronidazole 0.75% vaginal gel daily for 5 days.
    • Partner treatment not currently recommended.
    • Oral and vaginal regimens are similarly effective; oral metronidazole has more gastrointestinal side effects.6,7
  • Cost (7 days):8
    • Oral: Metronidazole 500mg $28.
    • Vaginal: Clindamycin 2% cream $65; metronidazole 0.75% gel $44.


Latest Tools for Practice
Derniers outils pour la pratique

#403 A Whiff of Prevention: Treating Male Partners to Reduce Bacterial Vaginosis Recurrence

Does treating male sexual partners of females undergoing treatment for bacterial vaginosis infection decrease recurrence?
Read Lire 0.25 credits available Crédits disponibles

#402 Nipple Confusion or Nonsense? Pacifiers and Breastfeeding Duration

In term infants, does restricting early use of pacifiers result in higher rates of breastfeeding up to 6 months of age?
Read Lire 0.25 credits available Crédits disponibles

#401 Vape Expectations: Are electronic cigarettes the real deal for smoking cessation? (Update)

Are nicotine-containing e-cigarettes more effective than other available options for smoking cessation?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session


Author(s)
Auteur(s)
  • Betsy Thomas BSc. Pharm
  • Caitlin Finley MSc MD CCFP

1. Vodstrcil LA, Plummer EL, Fairley CK, et al. N Engl J Med. 2025;392(10):947-957.

2. Schwebke JR, Lensing SY, Lee J, et al. Clin Infect Dis. 2021;73(3):e672-9.

3. Amaya-Guio J, Viveros-Carreño DA, Sierra-Barrios EM, et al. Cochrane Database Syst Rev. 2016 Oct 1;10:CD011701.

4. Centers for Disease Control and Prevention. Bacterial vaginosis – STI treatment guidelines [Internet]. Updated Jul 22, 2021. Available from: https://www.cdc.gov/std/treatment-guidelines/bv.htm Accessed Jul 31, 2025.

5. Alberta Health Services. Bugs & Drugs® antimicrobial reference [Internet]. Vancouver (BC): Do Bugs Need Drugs® Program; [updated unknown; cited 2025 Jul 31]. Available from: https://www.bugsanddrugs.org/434E4B36-9DF6-4B8A-9692-CD50D1A0FA94

6. Oduyebo OO, Anorlu RI, Ogunsola FT. Cochrane Database Syst Rev. 2009 Jul 8:(3):CD006055.

7. Hirai J, Arakawa Y, Kato H, et al. J Infect Chemother. 2025 Nov;31(11):102826.

8. Personal communication. Summerside Pharmacy, Edmonton Alberta. July 30, 2025.

Authors do not have any conflicts of interest to declare.